Skip to main content

Notice for dexrazoxane (Maxx Pharma Pty Ltd)

Active ingredients
dexrazoxane
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
powder for solution for injection/infusion
Indication
For use in the prevention of cardiotoxicity caused by anthracycline use
Therapeutic area
Cardiovascular

Help us improve the Therapeutic Goods Administration site